Ocaperidone

Names

[ Name ]:
Ocaperidone

[Synonym ]:
Ocaperidonum [INN-Latin]
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[l,2-a]pyrimidin-4-one
Ocaperidone (USAN)
Ocaperidona
Ocaperidone
UNII-26HUS7139V
Ocaperidonum
ocaperiodone
Ocaperidona [INN-Spanish]
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one

Biological Activity

[Description]:

Ocaperidone is an effective antipsychotic agent, acting as a potent 5-HT2 and dopamine D2 antagonist, and a 5-HT1A agonist, with Kis of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT2, a1-adrenergic receptor, dopamine D2, histamine H1 and a2-adrenergic receptor, respectively, and a pEC50 and pKi of 7.60 and 8.08 for h5-HT1A.

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor

Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

[Target]

Ki: 0.14 nM (5HT2), 0.46 nM (a1-adrenergic receptor), 0.75 nM (Dopamine D2), 1.6 nM (Histamine H1), 5.4 nM (a2-adrenergic receptor)[1] pEC50: 7.60 (h5-HT1A)[2] pKi: 8.08 (h5-HT1A)[2]

[In Vitro]

Ocaperidone has high affinify at 5-HT2 and dopamine D2, with Kis of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5HT2, a1-adrenergic, dopamine D2, histamine H1 and a2-adrenergic, respectively[1]. Ocaperidone shows 5-HT1A receptor agonist activity, with a pEC50 and pKi of 7.60 and 8.08[2].

[In Vivo]

Ocaperidone shows a potent occupation of 5HT2 receptor via in vivo binding in the frontal cortex of rats with an ED50 of 0.04 mg/kg, and 0.1 4-0.1 6 mg/kg for D2 receptor in the striatum and the nucleus accumbens[1]. Ocaperidone (R 79598) antagonizes dopamine D2 and 5-HT2, and shows a a partial generalization to buspirone with an ED50 of 0.163 mg/kg[3].

[Kinase Assay]

The membranes are prepared from frozen HA7 cells. Cells are harvested in ice-cold Tris-HCl pH 7.4, homogenized and centrifuged at 40 000×g, 4°C for 10 min. The pellet is suspended in the same buffer and centrifuged again. After the second centrifugation, the pellet is suspended in an assay buffer consisting of pargyline (10 μM) and CaCl2 (4 mM) in Tris-HCl (50 mM, pH 7.4). Membrane protein, 0.031-0.084 mg/tube, is incubated with [3H] 8-OH-DPAT (1 nM final concentration) and Ocaperidone at seven concentrations, for 30 min, room temperature. The reaction is terminated by filtration through Whatman filters, and radioactivity is counted by liquid scintillation spectrometry. The experiments are performed in triplicate. Data are analyzed using the non-linear curve fitting program EBDA/LIGAND. Results expressed as pKi values are means of three determinations[3].

[Animal admin]

Rats[1] Male Wistar rats (200 g) are treated subcutaneously with various dosages (0.01-10 or 2.5-40 mg/kg) of Ocaperidone dissolved in saline (injection of 1 mL of drug solution/100 g of body weight) or with saline (control); 1 hr thereafter the rats receive 1 μg/kg (5-10 μCi) [3H]spiperone by intravenous injection in the tail vein. The rats are sacrificed by decapitation 1 hr after the [3H]spiperone injection; the striatum, the nucleus accumbens, the tuberculum olfactorium, the frontal cortex, and the cerebellum are immediately dissected. The tissues are cooled on ice, weighed, and dissolved in 10 mL of Instagel II, in plastic counting vials. After 48 hr the radioactivity is counted; data are expressed in dpm, using external standard counting and referring to a quenched standard curve. The counted radioactivity is converted to pg of [3H]spiperone/mg of tissue. Four to six animals are treated at each drug dosage. For each drug and brain area, the values are averaged and graphically plotted versus the logarithm of the drug dosages. On each graph, values measured in the cerebellum are plotted; labeling in the cerebellum is taken as an indication of nonspecific tissue labeling[1].

[References]

[1]. Leysen JE, et al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol. 1992 Mar;41(3):494-508.

[2]. Cosi C, et al. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62.

[3]. Rijnders HJ, et al. The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity. Psychopharmacology (Berl). 1993;111(1):55-61.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.34g/cm3

[ Boiling Point ]:
588ºC at 760mmHg

[ Melting Point ]:
180-184°C

[ Molecular Formula ]:
C₂₄H₂₅FN₄O₂

[ Molecular Weight ]:
420.47900

[ Flash Point ]:
309.4ºC

[ Exact Mass ]:
420.19600

[ PSA ]:
63.64000

[ LogP ]:
3.95160

[ Vapour Pressure ]:
8.36E-14mmHg at 25°C

[ Index of Refraction ]:
1.667

Safety Information

[ Hazard Codes ]:
Xi

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.